Front Row Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $62.1K | Hold |
2,210
| – | – | 0.02% | 206 |
|
|
2025
Q4 | $55K | Hold |
2,210
| – | – | 0.02% | 211 |
|
|
2025
Q3 | $56.3K | Hold |
2,210
| – | – | 0.02% | 208 |
|
|
2025
Q2 | $53.6K | Sell |
2,210
-1,927
| -47% | -$44.9K | 0.02% | 210 |
|
|
2025
Q1 | $105K | Buy |
4,137
+10
| +0.2% | +$262 | 0.04% | 165 |
|
|
2024
Q4 | $109K | Sell |
4,127
-1,971
| -32% | -$53.5K | 0.04% | 164 |
|
|
2024
Q3 | $176K | Sell |
6,098
-7,515
| -55% | -$219K | 0.06% | 131 |
|
|
2024
Q2 | $381K | Buy |
13,613
+1,507
| +12% | +$41.5K | 0.13% | 87 |
|
|
2024
Q1 | $336K | Sell |
12,106
-42,471
| -78% | -$1.18M | 0.12% | 91 |
|
|
2023
Q4 | $1.57M | Sell |
54,577
-9,940
| -15% | -$300K | 0.72% | 39 |
|
|
2023
Q3 | $2.14M | Buy |
64,517
+197
| +0.3% | +$6.97K | 0.99% | 30 |
|
|
2023
Q2 | $2.36M | Buy |
64,320
+450
| +0.7% | +$17.5K | 1.05% | 25 |
|
|
2023
Q1 | $2.61M | Sell |
63,870
-376
| -0.6% | -$16.2K | 1.25% | 19 |
|
|
2022
Q4 | $3.29M | Sell |
64,246
-2,367
| -4% | -$113K | 1.7% | 10 |
|
|
2022
Q3 | $2.92M | Sell |
66,613
-120
| -0.2% | -$5.83K | 1.51% | 12 |
|
|
2022
Q2 | $3.5M | Sell |
66,733
-212
| -0.3% | -$10.8K | 1.72% | 10 |
|
|
2022
Q1 | $3.47M | Buy |
66,945
+1,826
| +3% | +$94.7K | 1.4% | 13 |
|
|
2021
Q4 | $3.85M | Sell |
65,119
-727
| -1% | -$36K | 1.43% | 13 |
|
|
2021
Q3 | $2.83M | Buy |
65,846
+86
| +0.1% | +$3.81K | 1.2% | 19 |
|
|
2021
Q2 | $3.21M | Buy |
65,760
+10,376
| +19% | +$403K | 1.32% | 15 |
|
|
2021
Q1 | $2.01M | Buy |
55,384
+709
| +1% | +$25.2K | 0.97% | 36 |
|
|
2020
Q4 | $2.01M | Sell |
54,675
-4,047
| -7% | -$148K | 1.03% | 30 |
|
|
2020
Q3 | $2.07M | Sell |
58,722
-1,720
| -3% | -$60.3K | 1.1% | 27 |
|
|
2020
Q2 | $1.88M | Sell |
60,442
-924
| -2% | -$31.4K | 1.16% | 24 |
|
|
2020
Q1 | $2.23M | Buy |
61,366
+3,245
| +6% | +$111K | 1.51% | 13 |
|
|
2019
Q4 | $2.16M | Sell |
58,121
-1,490
| -2% | -$53.1K | 1.41% | 15 |
|
|
2019
Q3 | $2.03M | Buy |
59,611
+1,162
| +2% | +$42.3K | 1.45% | 13 |
|
|
2019
Q2 | $2.4M | Sell |
58,449
-477
| -0.8% | -$18.9K | 1.75% | 7 |
|
|
2019
Q1 | $2.37M | Sell |
58,926
-306
| -0.5% | -$12.3K | 1.85% | 6 |
|
|
2018
Q4 | $2.45M | Sell |
59,232
-829
| -1% | -$34.4K | 2.13% | 6 |
|
|
2018
Q3 | $2.42K | Sell |
60,061
-1,600
| -3% | -$61.6K | 1.7% | 6 |
|
|
2018
Q2 | $2.22K | Buy |
61,661
+853
| +1% | +$29.1K | 1.42% | 9 |
|
|
2018
Q1 | $2.05M | Buy |
60,808
+635
| +1% | +$21.8K | 1.43% | 11 |
|
|
2017
Q4 | $2.07M | Buy |
+60,173
| New | +$2.05M | 1.65% | 8 |
|
Other funds holding PFE
VCM
VPM
Front Row Advisors's PFE Position: Q1 2026 in Review
Front Row Advisors held its Pfizer (PFE) position steady in Q1 2026 at 2,210 shares worth $62.1K. The position accounts for 0.02% of the portfolio, ranked #206.
Front Row Advisors first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.85M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Front Row Advisors held 2,210 shares of Pfizer worth $62.1K as of Q1 2026.
- Front Row Advisors left its Pfizer share count unchanged in Q1 2026.
- Pfizer made up 0.02% of Front Row Advisors's portfolio in Q1 2026, its #206 holding.
- Front Row Advisors first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- Front Row Advisors's Pfizer position peaked at $3.85M in Q4 2021.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.